227 related articles for article (PubMed ID: 17434608)
1. Glucagon-like peptide 1 (GLP-1) suppresses ghrelin levels in humans via increased insulin secretion.
Hagemann D; Holst JJ; Gethmann A; Banasch M; Schmidt WE; Meier JJ
Regul Pept; 2007 Oct; 143(1-3):64-8. PubMed ID: 17434608
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide 2 inhibits ghrelin secretion in humans.
Banasch M; Bulut K; Hagemann D; Schrader H; Holst JJ; Schmidt WE; Meier JJ
Regul Pept; 2006 Dec; 137(3):173-8. PubMed ID: 16928403
[TBL] [Abstract][Full Text] [Related]
3. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.
Meier JJ; Kemmeries G; Holst JJ; Nauck MA
Diabetes; 2005 Jul; 54(7):2212-8. PubMed ID: 15983224
[TBL] [Abstract][Full Text] [Related]
4. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.
Meier JJ; Gethmann A; Nauck MA; Götze O; Schmitz F; Deacon CF; Gallwitz B; Schmidt WE; Holst JJ
Am J Physiol Endocrinol Metab; 2006 Jun; 290(6):E1118-23. PubMed ID: 16403774
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans.
Meier JJ; Gethmann A; Götze O; Gallwitz B; Holst JJ; Schmidt WE; Nauck MA
Diabetologia; 2006 Mar; 49(3):452-8. PubMed ID: 16447057
[TBL] [Abstract][Full Text] [Related]
6. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses.
Little TJ; Pilichiewicz AN; Russo A; Phillips L; Jones KL; Nauck MA; Wishart J; Horowitz M; Feinle-Bisset C
J Clin Endocrinol Metab; 2006 May; 91(5):1916-23. PubMed ID: 16492694
[TBL] [Abstract][Full Text] [Related]
7. Impact of exogenous hyperglucagonemia on postprandial concentrations of gastric inhibitory polypeptide and glucagon-like peptide-1 in humans.
Meier JJ; Ritter PR; Jacob A; Menge BA; Deacon CF; Schmidt WE; Nauck MA; Holst JJ
J Clin Endocrinol Metab; 2010 Aug; 95(8):4061-5. PubMed ID: 20501678
[TBL] [Abstract][Full Text] [Related]
8. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
[TBL] [Abstract][Full Text] [Related]
9. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
[TBL] [Abstract][Full Text] [Related]
10. Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion.
Salehi M; Vahl TP; D'Alessio DA
J Clin Endocrinol Metab; 2008 Dec; 93(12):4909-16. PubMed ID: 18827000
[TBL] [Abstract][Full Text] [Related]
11. Ghrelin Impairs Prandial Glucose Tolerance and Insulin Secretion in Healthy Humans Despite Increasing GLP-1.
Tong J; Davis HW; Gastaldelli A; D'Alessio D
J Clin Endocrinol Metab; 2016 Jun; 101(6):2405-14. PubMed ID: 27055279
[TBL] [Abstract][Full Text] [Related]
12. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.
Nauck MA; Heimesaat MM; Behle K; Holst JJ; Nauck MS; Ritzel R; Hüfner M; Schmiegel WH
J Clin Endocrinol Metab; 2002 Mar; 87(3):1239-46. PubMed ID: 11889194
[TBL] [Abstract][Full Text] [Related]
13. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
Willms B; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Nauck MA
J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
[TBL] [Abstract][Full Text] [Related]
14. A liquid mixed meal or exogenous glucagon-like peptide 1 (GLP-1) do not alter plasma leptin concentrations in healthy volunteers.
Drewes C; Nauck MA; Horn R; Holst J; Schmiegel W; Brabant G
Acta Diabetol; 1997 Oct; 34(3):230-4. PubMed ID: 9401646
[TBL] [Abstract][Full Text] [Related]
15. Absence of a memory effect for the insulinotropic action of glucagon-like peptide 1 (GLP-1) in healthy volunteers.
Meier S; Hücking K; Ritzel R; Holst JJ; Schmiegel WH; Nauck MA
Horm Metab Res; 2003 Sep; 35(9):551-6. PubMed ID: 14517773
[TBL] [Abstract][Full Text] [Related]
16. Jejunal feeding is followed by a greater rise in plasma cholecystokinin, peptide YY, glucagon-like peptide 1, and glucagon-like peptide 2 concentrations compared with gastric feeding in vivo in humans: a randomized trial.
Luttikhold J; van Norren K; Rijna H; Buijs N; Ankersmit M; Heijboer AC; Gootjes J; Hartmann B; Holst JJ; van Loon LJ; van Leeuwen PA
Am J Clin Nutr; 2016 Feb; 103(2):435-43. PubMed ID: 26762368
[TBL] [Abstract][Full Text] [Related]
17. Ghrelin attenuates the inhibitory effects of glucagon-like peptide-1 and peptide YY(3-36) on food intake and gastric emptying in rats.
Chelikani PK; Haver AC; Reidelberger RD
Diabetes; 2006 Nov; 55(11):3038-46. PubMed ID: 17065340
[TBL] [Abstract][Full Text] [Related]
18. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
Schirra J; Sturm K; Leicht P; Arnold R; Göke B; Katschinski M
J Clin Invest; 1998 Apr; 101(7):1421-30. PubMed ID: 9525985
[TBL] [Abstract][Full Text] [Related]
19. Intravenous CCK-8, but not GLP-1, suppresses ghrelin and stimulates PYY release in healthy men.
Brennan IM; Otto B; Feltrin KL; Meyer JH; Horowitz M; Feinle-Bisset C
Peptides; 2007 Mar; 28(3):607-11. PubMed ID: 17129639
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.
Näslund E; Gutniak M; Skogar S; Rössner S; Hellström PM
Am J Clin Nutr; 1998 Sep; 68(3):525-30. PubMed ID: 9734726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
